According to Trevena's latest financial reports the company's current revenue (TTM) is $3.2 M. In 2022 the company made a revenue of -$0.42 M a decrease over the years 2021 revenue that were of $0.56 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $3.2 M | -867.22% |
2022 | -$0.42 M | -173.72% |
2021 | $0.56 M | -81.52% |
2020 | $3.06 M | 9800% |
2019 | $0.03 M | -99.46% |
2018 | $5.73 M | |
2017 | N/A | -100% |
2016 | $3.75 M | -40% |
2015 | $6.25 M | |
2014 | N/A | -100% |
2013 | $0.13 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Amgen AMGN | $28.19 B | 878,914.66% | ๐บ๐ธ USA |
Merck MRK | $60.11 B | 1,874,362.11% | ๐บ๐ธ USA |
Flexion Therapeutics
FLXN | $0.10 B | 3,030.65% | ๐บ๐ธ USA |
Cytokinetics
CYTK | $7.53 M | 134.80% | ๐บ๐ธ USA |
AcelRx Pharmaceuticals
ACRX | $0.65 M | -79.70% | ๐บ๐ธ USA |
Cara Therapeutics
CARA | $20.96 M | 553.82% | ๐บ๐ธ USA |
Arena Pharmaceuticals
ARNA | $0.37 M | -88.37% | ๐บ๐ธ USA |